SRA
DYN icon

Summit Rock Advisors’s Dyne Therapeutics DYN Stock Holding History

Summit Rock Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-34,887
Closed -$240K – 7
2022
Q2 		$240K Hold
34,887
– – 0.2% 8
2022
Q1 		$336K Hold
34,887
– – 0.21% 6
2021
Q4 		$415K Buy
+34,887
New +$490K 0.25% 8

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Summit Rock Advisors's DYN Position: Q3 2022 in Review

Summit Rock Advisors sold out of Dyne Therapeutics (DYN) in Q3 2022, closing a stake of 34,887 shares — an estimated $240K sold.

Summit Rock Advisors first reported a position in DYN in Q4 2021 and held it in 3 quarters. The position peaked at $415K in Q4 2021. 102 funds tracked by Wall St. Rank hold DYN as of Q3 2022.

  • Summit Rock Advisors reported no remaining Dyne Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Summit Rock Advisors sold 34,887 Dyne Therapeutics shares in Q3 2022, an estimated $240K.
  • Summit Rock Advisors first reported a position in Dyne Therapeutics in Q4 2021 and held it in 3 quarters.
  • Summit Rock Advisors's Dyne Therapeutics position peaked at $415K in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2022.

Based on Summit Rock Advisors's 13F filing for Q3 2022, filed 2 Nov 2022.